KR840006765A - 지속성 방출 고형 제형의 제조방법 - Google Patents

지속성 방출 고형 제형의 제조방법 Download PDF

Info

Publication number
KR840006765A
KR840006765A KR1019830005160A KR830005160A KR840006765A KR 840006765 A KR840006765 A KR 840006765A KR 1019830005160 A KR1019830005160 A KR 1019830005160A KR 830005160 A KR830005160 A KR 830005160A KR 840006765 A KR840006765 A KR 840006765A
Authority
KR
South Korea
Prior art keywords
tablet
sustained
release
layer
medicament
Prior art date
Application number
KR1019830005160A
Other languages
English (en)
Other versions
KR900007311B1 (ko
Inventor
에이. 조글리오 마이클
Original Assignee
게리 디이. 스트리트
메렐 다우 파마슈티컬스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디이. 스트리트, 메렐 다우 파마슈티컬스 인코포레이티드 filed Critical 게리 디이. 스트리트
Publication of KR840006765A publication Critical patent/KR840006765A/ko
Application granted granted Critical
Publication of KR900007311B1 publication Critical patent/KR900007311B1/ko

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용없음

Description

지속성 방출 고형 제형의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (18)

  1. 핵정에 하나 이상의 지속성 방출 외층을 코팅시킴으로서 약제를 실질적으로 0차 방출시키는 정제를 제조하는 방법에 있어서, 핵정 및 하나이상의 지속성-방출 외층은 약제, 친수성 겔 및 부형제의 혼합물로 주로 이루어지며, 친수성 겔의 농도는 핵정 및 각각의 지속성-방출 외층에서 거의 일정하며 핵정 또는 특정한 지속성-방출 층의 약제량은 다음식에 의해 결정됨을 특징으로 하는 방법.
    여기에서, DL은 핵정 또는 특정한 지속성-방출층중의 약제량이며, DT는 정제의 지속성-방출 부위중 약제의 총 양이고, RD는 필요한 약제량을 구하고자 하는 핵정 또는 외층의 미분반경이며, RT는 정제의지속성-방출 부위의 반경이다.
  2. 제1항에 있어서, 정제가, 1개의 외층을 갖는 방법.
  3. 제2항에 있어서, 친수성 겔이 하이드록시프로필메틸셀룰로스인 방법.
  4. 제3항에 있어서, 하이드록시프로필메틸셀룰로스의 점도가 4000센티포아스인 방법.
  5. 제2항에 있어서, 약제가 터부탈린인 방법.
  6. 제2항에 있어서, 약제가 터페나딘인 방법.
  7. 제2항에 있어서, 약제가 슈도에페드린 HCI인 방법.
  8. 제2항에 있어서, 정제가 외부 비-지속성, 방출층을 갖는 방법.
  9. 제8항에 있어서, 외부, 비-지속성, 방출층의 약제가 터페나딘이며 핵정 및 지속성-방출, 외층의 약제가 슈도에페드린 HCI인 방법.
  10. 제1항에 있어서, 정제가 2내지 4개의 외층을 갖는 방법.
  11. 제10항에 있어서, 친수성 겔이 하이드록시프로필 메틸셀룰로스인 방법.
  12. 제11항에 있어서, 하이드록시프로필메틸렐룰로스의 점도가 4000센티포아스인 방법.
  13. 제10항에 있어서, 약제가 터부탈린인 방법.
  14. 제10항에 있어서, 약제가 터페나딘인 방법.
  15. 제10항에 있어서, 약제가 슈도에페드린 HCI인 방법.
  16. 제1항에 있어서, 정제가 2개의 지속성-방출, 외층을 갖는 방법.
  17. 제16항에 있어서, 정제가 외부 비-지속성, 방출 층을 갖는 방법.
  18. 제17항에 있어서, 외부의 비-지속성, 방출층의 약제는 터페나딘이며 지속성-방출층 및 핵정의 약제는 슈도에페드린 HCI인 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830005160A 1982-11-01 1983-10-31 지속성 방출 고형 제형의 제조방법 KR900007311B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US43810082A 1982-11-01 1982-11-01
US438100 1982-11-01
US438,100 1982-11-01
US53612883A 1983-09-27 1983-09-27
US536,128 1983-09-27

Publications (2)

Publication Number Publication Date
KR840006765A true KR840006765A (ko) 1984-12-03
KR900007311B1 KR900007311B1 (ko) 1990-10-08

Family

ID=27031546

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830005160A KR900007311B1 (ko) 1982-11-01 1983-10-31 지속성 방출 고형 제형의 제조방법

Country Status (13)

Country Link
EP (1) EP0111144B1 (ko)
KR (1) KR900007311B1 (ko)
AU (1) AU554377B2 (ko)
CA (1) CA1220137A (ko)
DE (1) DE3368011D1 (ko)
DK (1) DK499183A (ko)
ES (1) ES8607008A1 (ko)
GR (1) GR78740B (ko)
IE (1) IE56182B1 (ko)
IL (1) IL70071A (ko)
NO (1) NO163356C (ko)
NZ (1) NZ206094A (ko)
PH (1) PH20332A (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE33994E (en) * 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4624848A (en) * 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4749576A (en) * 1984-05-10 1988-06-07 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
DE3486409T2 (de) * 1984-08-17 1996-04-25 Wellcome Found Zusammensetzung zur kontrollierten Abgabe eines Wirkstoffs.
US5219575A (en) * 1987-06-26 1993-06-15 Duphar International Research B.V. Compositions with controlled zero-order delivery rate and method of preparing these compositions
EP0297650A1 (en) * 1987-06-26 1989-01-04 Duphar International Research B.V Compositions with controlled zero-order delivery rate and method of preparing these compositions
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US5085865A (en) * 1989-04-12 1992-02-04 Warner-Lambert Company Sustained release pharmaceutical preparations containing an analgesic and a decongestant
US5198227A (en) * 1990-01-22 1993-03-30 Mcneil-Ppc, Inc. Dual subcoated simulated capsule medicament
DK0707475T3 (da) * 1993-06-14 1997-12-29 Janssen Pharmaceutica Nv Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
US5484607A (en) * 1993-10-13 1996-01-16 Horacek; H. Joseph Extended release clonidine formulation
US5451409A (en) * 1993-11-22 1995-09-19 Rencher; William F. Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
DE19608423A1 (de) * 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US6197340B1 (en) 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
DE10031043A1 (de) 2000-06-26 2002-02-14 Bayer Ag Retardzubereitungen von Chinolonantibiotika und Verfahren zu ihrer Herstellung
KR100402053B1 (ko) * 2000-09-28 2003-10-17 한국화학연구원 항생제의 서방성 임플란트 제제
ES2663873T3 (es) * 2001-10-29 2018-04-17 Massachusetts Institute Of Technology Forma farmacéutica con perfil de liberación de orden cero fabricada por impresión tridimensional
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
CA2689978A1 (en) 2007-06-08 2008-12-18 Addrenex Pharmaceuticals, Inc. Extended release formulation and method of treating adrenergic dysregulation
CN103370058A (zh) 2010-12-22 2013-10-23 普渡制药公司 包覆的抗篡改控制释放剂型
CA2822769C (en) 2010-12-23 2016-10-04 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
CA2978680A1 (en) 2015-03-04 2016-09-09 Arnold Forbes Compositions and methods for treating drug addiction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1139869A (en) * 1966-01-06 1969-01-15 Moore Medicinal Products Ltd Improvements in or relating to tablets
US3965255A (en) * 1974-05-01 1976-06-22 E. E. Eljim Ecology Ltd. Controlled drug releasing preparations
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
US4122157A (en) * 1977-03-04 1978-10-24 Richardson-Merrell Inc. Nitrofurantoin sustained release tablet
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4291015A (en) * 1979-08-14 1981-09-22 Key Pharmaceuticals, Inc. Polymeric diffusion matrix containing a vasodilator

Also Published As

Publication number Publication date
GR78740B (ko) 1984-10-02
NZ206094A (en) 1986-10-08
ES8607008A1 (es) 1986-06-16
CA1220137A (en) 1987-04-07
PH20332A (en) 1986-12-02
NO163356C (no) 1990-05-16
DE3368011D1 (en) 1987-01-15
DK499183D0 (da) 1983-10-31
IL70071A (en) 1987-12-31
AU2080383A (en) 1984-05-10
DK499183A (da) 1984-05-02
NO833961L (no) 1984-05-02
AU554377B2 (en) 1986-08-21
NO163356B (no) 1990-02-05
ES526901A0 (es) 1986-06-16
EP0111144A1 (en) 1984-06-20
EP0111144B1 (en) 1986-12-03
IE832543L (en) 1984-05-01
IL70071A0 (en) 1984-01-31
IE56182B1 (en) 1991-05-08
KR900007311B1 (ko) 1990-10-08

Similar Documents

Publication Publication Date Title
KR840006765A (ko) 지속성 방출 고형 제형의 제조방법
KR870700344A (ko) 유효 화합물을 서서히 방출하는 신규 약제, 그의 제조방법 및 이신규 제제물의 용도
ATE9695T1 (de) Antihistamine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DE3676626D1 (de) Verfahren zur herstellung einer darreichungs- und dosierungsform fuer arzneimittel-wirkstoffe, reagentien oder andere wirkstoffe.
KR860000068A (ko) 약제에의 지효성 제공방법
KR860000800A (ko) 용해 유체내의 유효성분을 영차 방출하는 시방정 및 이의 제조방법
NO20073429L (no) Anvendelse av et antistoff mot interleukin-6-reseptor for fremstilling av et farmasoytisk preparat
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
DE69104991D1 (de) Mometason-furoate-monohydrat, verfahren zu seiner herstellung und das enthaltende pharmazeutische zusammensetzungen.
FR2511357B1 (fr) Cis-platine microcristallin, son procede de preparation et composition pharmaceutique le contenant
ATE20518T1 (de) Trockene pulverige allergenzusammensetzung und verfahren zu deren herstellung.
ATE444737T1 (de) Pharmakologisch aktive ionisierbare substanzen enthaltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
KR950701214A (ko) 눈에 투여를 위한 약제학적 투약 형태 및 그 제조방법(galenic form for ocular administraion and process for the preparation of same)
DE2967701D1 (de) A-21978 genannte antibiotische mischung, verfahren zu ihrer herstellung, ihre pharmazeutischen zusammensetzungen und produzierender mikroorganismus.
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
AT363936B (de) Verfahren zur herstellung von neuen cyproheptadinderivaten und von deren pharmazeutisch verwendbaren salzen sowie optischen isomeren
NL169076B (nl) Werkwijze voor het bereiden of vervaardigen van farmacologische preparaten met een analgetische en antipyretische werking, alsmede werkwijze voor het bereiden van geneeskrachtige verbindingen, welke geschikt zijn voor gebruik in dergelijke preparaten.
DE3777122D1 (de) Alkansulfonanilid-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ATE1734T1 (de) Schmerzstillende tablette und verfahren zu deren herstellung.
DE3681334D1 (de) Androstane-17-beta-carbonsaeureester, verfahren zu deren herstellung und pharmazeutische praeparate die diese enthalten.
Rojanasthien et al. Bioequivalence study of modified‐release gliclazide tablets in healthy volunteers
NL170283C (nl) Werkwijze voor het bereiden van verbindingen met een analgetische en ontstekingsremmende activiteit, alsmede daarmede vervaardigde, gevormde geneesmiddelen.
AR013352A1 (es) Uso de un sensibilizador a insulina y un agente antihiperglucemico para la preparacion de un medicamento para el tratamiento de la diabetes mellitus ycondiciones asociadas a la misma y una composicion farmaceutica.
BRPI0307319B8 (pt) forma de dosagem oral para liberação controlada de droga e processo para sua preparação
FR2391202A1 (fr) Triazines-1,2,4 substituees, actives pharmacologiquement et medicaments contenant ces triazines

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
LAPS Lapse due to unpaid annual fee